8-K: Oncotelic Closes Final Tranche of $25K Unit Offering

Oncotelic Therapeutics, Inc. announced the completion of the third and final tranche of its unit offering, raising capital through convertible notes and warrants.

Summary

• Oncotelic Therapeutics, Inc. completed the third and final tranche (Tranche 3) of its unit offering on December 31, 2025.
• Tranche 3 involved the issuance of 44 units to 22 accredited investors, marking the conclusion of the offering.
• The total offering was for up to 500 units, with each unit consisting of a $25,000.00 principal amount note and warrants.
• Notes bear 12% annual interest and are due two years from the final closing of the Offering.
• Notes are convertible into up to 250,000 shares of Oncotelic Common Stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc. Common Stock at $1.00 per share, subject to anti-dilution provisions.
• Each unit also includes 250,000 warrants for Oncotelic Common Stock at $0.12 per share or 25,000 EdgePoint Warrants at $1.25 per share, exercisable for two years and subject to anti-dilution provisions.
• Existing 2023 PPM Notes are considered paid off, and prior 2023 warrants have their expiration dates extended by two years.
• Investors can convert EdgePoint shares (issued at $1.00) into Oncotelic shares at a 1:10 ratio (1 EdgePoint share for 10 Oncotelic shares).
• A Registration Rights Agreement was executed for the newly issued shares and those issuable upon warrant exercise.
• The issuance was exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.

Sentiment

Score: 6

Explanation: The completion of a capital raise is generally positive for funding operations, but the high interest rate and potential for dilution introduce some caution. The flexibility for investors is a positive, but the non-participation of some 2023 PPM investors is a slight negative.

Positives

• Successful completion of the final tranche of a capital raise, indicating investor confidence in the offering structure and providing necessary funding.
• Extension of prior 2023 warrants for an additional two years, potentially retaining investor interest and providing continued upside potential.
• Provides flexibility for investors to convert into either Oncotelic or EdgePoint stock, or to convert EdgePoint shares into Oncotelic shares, offering diversified exposure.

Negatives

• Issuance of convertible notes and warrants could lead to significant dilution for existing shareholders if converted or exercised.
• Two accredited investors from the 2023 PPM did not participate in the current offering, which could suggest a lack of continued interest from some prior investors.
• The 12% annual interest rate on the notes is relatively high, indicating a higher cost of capital for the company.
• The shares and warrants are unregistered, limiting their immediate liquidity for investors.

Risks

• Dilution Risk: Conversion of notes and exercise of warrants will increase the number of outstanding shares, potentially diluting the value of existing common stock.
• Market Price Volatility: The conversion prices and warrant exercise prices are fixed, but the market price of Oncotelic and EdgePoint common stock could fluctuate, affecting the value of the conversion/exercise rights.
• Liquidity Risk: The issued shares and warrants are unregistered, meaning they cannot be freely traded in the public market without registration or an applicable exemption.
• Dependence on Subsidiary Performance: The option to convert into EdgePoint stock or convert EdgePoint shares into Oncotelic shares links Oncotelic's value to the performance of its minority-owned subsidiary, EdgePoint AI, Inc.

Future Outlook

The offering's notes are due and payable on the 2-year anniversary of the final closing, and warrants are exercisable for two years after issuance, indicating a future period of potential conversions and exercises.

Management Comments

• The Company completed entering into subscription agreements with certain accredited investors.
• Tranche 3 is the last tranche under the Offering.
• The Company shall consider the old 2023 note as paid off and the contribution towards the new Notes as fully paid for.
• The prior 2023 issued warrants shall continue to vest as before and on the same terms and conditions contained in such prior issued warrant, for an additional period of two years extending their expiration date to the 2-year anniversary.
• The Company will permit the Investor to convert their shareholding in Edgepoint into shares of Oncotelic at the rate of $0.10 per share of Oncotelic.

Industry Context

This capital raise through convertible notes and warrants is a common financing strategy for smaller biotechnology or technology companies like Oncotelic, especially those with a consolidated subsidiary like EdgePoint AI, Inc., to secure funding for operations and development without immediate equity dilution at potentially lower valuations. The high interest rate on the notes suggests a higher risk profile or limited access to traditional debt financing.

Comparison to Industry Standards

• The 12% annual interest rate on the notes is relatively high compared to typical corporate debt for established companies, but may be within range for early-stage biotech or AI firms with higher risk profiles and limited access to conventional financing.
• The conversion prices ($0.10 for Oncotelic, $1.00 for EdgePoint) and warrant exercise prices ($0.12 for Oncotelic, $1.25 for EdgePoint) are specific to the company's current valuation and growth prospects, making direct comparisons difficult without more detailed financial data for comparable private placements in similar-stage companies.
• The inclusion of both parent company and subsidiary conversion/warrant options is a less common but strategic approach, potentially offering investors diversified exposure to both the biotech and AI sectors within the same investment, which could be attractive in a diversified portfolio context.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution from the conversion of notes and exercise of warrants. Existing shareholders' percentage ownership could decrease.
• Investors (Accredited): Receive convertible notes with a 12% interest rate and warrants, offering potential upside through equity conversion in either Oncotelic or its subsidiary EdgePoint. They also gain registration rights for future liquidity.
• Company (Oncotelic): Secures capital for operations and development, but incurs a relatively high cost of capital (12% interest) and potential future dilution.

Next Steps

• Notes will be due and payable on the 2-year anniversary of the final closing of the Offering.
• Warrants will be exercisable for two years after issuance.
• Shares issued upon conversion of notes or exercise of warrants will be subject to the Registration Rights Agreement, facilitating future liquidity.

Key Dates

Recommendation

While the successful completion of a capital raise provides necessary funding, the terms of the offering, including a high 12% interest rate on convertible notes and significant potential for dilution from warrants and conversions, present a mixed outlook. The flexibility offered to investors with dual conversion options (Oncotelic or EdgePoint) is a positive, but the non-participation of some prior investors and the unregistered nature of the securities add a layer of uncertainty. Investors should hold to monitor the company's use of funds, progress in its pipeline/operations, and the impact of future conversions/exercises on the stock price before making further investment decisions.

Keywords

Oncotelic Therapeutics, OTLC, EdgePoint AI, Convertible Notes, Warrants, Private Placement, Equity Financing, SEC 8-K, Capital Raise, Accredited Investors, Dilution, Registration Rights